Clinical Trial

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Study acronym: ProbeTILity
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-20; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07255664
Lead Sponsor CuraCell TX AB
Collaborators: Zellwerk GmbH, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Krebsforschung Rhein-Main e.V.
Conditions Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced
Enrollment 12 participants
Start Date 2025-11-13
Primary Completion 2027-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-22